Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treating lymphoma is now a bit EZ-er.

Blood advances - 27 Apr 2021

Morin Ryan D, Arthur Sarah E, Assouline Sarit

Abstract excerpt

Tazemetostat represents the first epigenetic therapy approved for the treatment of follicular lymphoma (FL). It inhibits the activity of the enhancer of zeste homolog 2 (EZH2) histone methyltransferase, the first of a multitude of epigenetic regulators that have been identified as recurrently mutated in FL and germinal center diffuse large B-cell lymphoma. In this review, we discuss the initial discovery and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphoma, Large B-Cell, Diffuse
Share to Mutation
Share to Cancer-related gene regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenetics and DNA Methylation

Share to Germinal Center

Share to Lymphoma Diagnosis and Treatment

Share to Lymphoma, Follicular

Source

Open in PubMed Open full text

Identifiers

PMID: 33904892
DOI: 10.1182/bloodadvances.2020002773
PMCID: PMC8095133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treating lymphoma is now a bit EZ-er.PMID 33904892Read ↗

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.Semantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.Semantic proximity Read ↗

EZH2 mutations are frequent and represent an early event in follicular lymphoma.Semantic proximity Read ↗

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.Semantic proximity Read ↗

The follicular lymphoma epigenome regulates its microenvironment.Semantic proximity Read ↗

Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?Semantic proximity Read ↗

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.Semantic proximity Read ↗

Comparative Analysis of the Clinicopathological Features of Follicular Lymphoma With and Without EZH2 Y646 Mutation.Semantic proximity Read ↗

EZH2: an epigenetic gatekeeper promoting lymphomagenesis.Semantic proximity Read ↗

Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.Semantic proximity Read ↗

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.